Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion Pharmaceuticals closed its initial public offering on April 20, 2021, raising $501.8 million through the sale of 27,878,787 shares of Class A common stock at $18.00 per share. This includes the full exercise of the underwriters' option for an additional 3,636,363 shares. Trading commenced on the Nasdaq Global Select Market under the ticker RXRX on April 16, 2021. Goldman Sachs and J.P. Morgan were the lead book-running managers for the offering.
Recursion Pharmaceuticals has priced its initial public offering (IPO) of 24,242,424 shares of Class A common stock at $18.00 per share, aiming to raise $436.4 million in gross proceeds. The shares will start trading on the Nasdaq under the symbol RXRX on April 16, 2021, with the offering expected to close by April 20, 2021. The underwriters have a 30-day option to purchase an additional 3,636,363 shares. Goldman Sachs & Co. LLC and J.P. Morgan are leading the underwriting for this offering.